Almlén Andreas, Stichtenoth Guido, Linderholm Bim, Haegerstrand-Björkman Marie, Robertson Bengt, Johansson Jan, Curstedt Tore
Dept. of Molecular Medicine and Surgery, Section of Clinical Chemistry, Bldg. L2:03, Karolinska Univ. Hospital, SE-171 76 Stockholm, Sweden.
J Appl Physiol (1985). 2008 Apr;104(4):1101-8. doi: 10.1152/japplphysiol.00865.2007. Epub 2008 Feb 14.
Modified natural surfactant preparations, used for treatment of respiratory distress syndrome in premature infants, contain phospholipids and the hydrophobic surfactant protein (SP)-B and SP-C. Herein, the individual and combined effects of SP-B and SP-C were evaluated in premature rabbit fetuses treated with airway instillation of surfactant and ventilated without positive end-expiratory pressure. Artificial surfactant preparations composed of synthetic phospholipids mixed with either 2% (wt/wt) of porcine SP-B, SP-C, or a synthetic poly-Leu analog of SP-C (SP-C33) did not stabilize the alveoli at the end of expiration, as measured by low lung gas volumes of approximately 5 ml/kg after 30 min of ventilation. However, treatment with phospholipids containing both SP-B and SP-C/SP-C33 approximately doubled lung gas volumes. Doubling the SP-C33 content did not affect lung gas volumes. The tidal volumes were similar in all groups receiving surfactant. This shows that SP-B and SP-C exert different physiological effects, since both proteins are needed to establish alveolar stability at end expiration in this animal model of respiratory distress syndrome, and that an optimal synthetic surfactant probably requires the presence of mimics of both SP-B and SP-C.
用于治疗早产儿呼吸窘迫综合征的改良天然表面活性剂制剂含有磷脂以及疏水性表面活性剂蛋白(SP)-B和SP-C。在此,在经气道滴注表面活性剂并在无呼气末正压的情况下进行通气的早产兔胎儿中评估了SP-B和SP-C的单独作用及联合作用。由合成磷脂与2%(重量/重量)的猪SP-B、SP-C或SP-C的合成聚亮氨酸类似物(SP-C33)混合组成的人工表面活性剂制剂在通气30分钟后,通过约5毫升/千克的低肺气体量测量,在呼气末并未稳定肺泡。然而,用同时含有SP-B和SP-C/SP-C33的磷脂进行治疗可使肺气体量增加约一倍。将SP-C33含量加倍并不影响肺气体量。接受表面活性剂治疗的所有组的潮气量相似。这表明SP-B和SP-C发挥不同的生理作用,因为在这个呼吸窘迫综合征动物模型中,两种蛋白质对于在呼气末建立肺泡稳定性都是必需的,并且一种最佳的合成表面活性剂可能需要同时存在SP-B和SP-C的模拟物。